Issue Archive

Research progress of endogenous bone marrow-derived mesenchymal stem cells in pulmonary fibrosis

LI Xiao-Hong¹, LUO Zi-Qiang^2,*

¹Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China；²Department of Physiology, School of Basic Medical Science, Central South University, Changsha 410013, China

Abstract

Pulmonary fibrosis is a chronic, diffuse, interstitial lung disease involving the pulmonary interstitium, alveoli, and bronchioles caused by various causes. There is no effective treatment. Currently, exogenous bone marrow-derived mesenchymal stem cells (BM-MSCs) transplantation has attracted much attention as a new stem cell therapy in the treatment of pulmonary fibrosis. Less attention has been paid to the functional status of endogenous BM-MSCs during pulmonary fibrosis. Based on summary on the anti-pulmonary fibrosis effect of BM-MSCs and its mechanism, this review further discusses the abnormal changes of bone marrow function in animals with pulmonary fibrosis and the role of glutamate NMDA receptor overactivation in mediating the functional inhibition of endogenous BM-MSCs induced by pulmonary fibrosis. This will provide potential ideas for finding effective treatments for pulmonary fibrosis.

Key words: pulmonary fibrosis; bone marrow-derived mesenchymal stem cells; NMDA receptor

Received: 2019-12-11　　Accepted: 2020-03-20

Corresponding author: 罗自强　　E-mail: E-mail: luoziqiang@csu.edu.cn

DOI: 10.13294/j.aps.2020.0055

Citing This Article：

LI Xiao-Hong, LUO Zi-Qiang. Research progress of endogenous bone marrow-derived mesenchymal stem cells in pulmonary fibrosis. Acta Physiol Sin 2020; 72 (5): 597-604 (in Chinese with English abstract).